Company intelligence / Profile preview
STORM Therapeutics
Cambridge, England, UKstormtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The first company to advance an RNA modifying enzyme inhibitor (STC-15) into clinical trials Dosed first patient in Phase I trial for solid tumors in November 2022 (NCT05584111) Preclinical data shows immune activation and tumor growth inhibition through METTL3 inhibition
- Therapeutic areas
- OncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Evotec AG
Beyond the preview
Go deeper on STORM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STORM Therapeutics.